Bio-Rad Laboratories, Inc.
BIO · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $8 | $7 | $7 | $9 |
| - Cash | $0 | $0 | $1 | $0 |
| + Debt | $1 | $1 | $1 | $1 |
| Enterprise Value | $9 | $8 | $8 | $10 |
| Revenue | $1 | $1 | $1 | $1 |
| % Growth | 0.2% | 11.3% | -12.3% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 52.6% | 53% | 52.3% | 51.2% |
| EBITDA | -$0 | $0 | $0 | -$1 |
| % Margin | -58.9% | 73.2% | 22.8% | -127% |
| Net Income | -$0 | $0 | $0 | -$1 |
| % Margin | -52.4% | 48.8% | 10.9% | -107.2% |
| EPS Diluted | -12.7 | 11.67 | 2.29 | -25.57 |
| % Growth | -208.8% | 409.6% | 109% | – |
| Operating Cash Flow | $0 | $0 | $0 | $0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | $0 | $0 | $0 |